Skip to main content

Table 2 Predictors of biochemical recurrence-free survival in patients with Nadir PSA < 0.06 ng/mL

From: Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

Factors

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age (≤ 70 versus > 70 years)

0.530 (0.145–1.937)

0.337

–

–

T stage (T1-2 versus T3-4)

3.074 (0.972–9.719)

0.056

2.431 (0.712–8.297)

0.156

Gleason Score (≤ 7 versus 8–10)

1.045 (0.340–3.211)

0.939

–

–

PSA at presentation (≤ 20 ng/mL versus > 20 ng/mL)

1.088 (0.364–3.255)

0.880

–

–

Total ADT duration *

0.327 (0.109–0.978)

0.046

0.224 (0.070–0.720)

0.012

Time to nadir PSA (cut-off 6 months**)

3.387 (1.041–11.023)

0.043

4.369 (1.096–17.421)

0.037

  1. *Comparing the use of ADT for at least 12 months versus 9 months or less
  2. **Median time to nadir PSA